Metformin Use in Type 2 Diabetes Mellitus Tuberculosis Co-infection and the Risk of Lactic Acidosis: A Case Risk-Study

Bernadette Dian Novita1*, Endang Isbandiati Soediono1, Ni Made Mertaniasih2, Agung Pranoto3 and Wuryani2

1Department of Pharmacology and Therapy, Faculty of Medicine Widya Mandala Catholic University Surabaya, Indonesia
2Faculty of Medicine, Airlangga University, Indonesia
3Department of Clinical Microbiology, Faculty of Medicine, Airlangga University/ Dr. Soetomo Hospital, Indonesia

*Corresponding author: Bernadette Dian Novita, Department of Pharmacology and Therapy, Medical Faculty, Widya Mandala Catholic University Surabaya, Indonesia, Tel: +62-812-3547540; E-mail: diannovitakrisdianto@yahoo.co.id

Abstract

Metformin (MET) has possibilities to be utilized as an adjunct of TB therapy in controlling the growth of Mycobacterium tuberculosis (MtB). MET enhances the production of mitochondrial reactive oxygen species and facilitates phagosome-lysosome fusion, those mechanism are important in MtB elimination. Moreover, MET associated lactic acidosis (MALA) needs to be considered and the incidence of MALA in patients with type 2 DM-TB co-infection remains unknown. This result contributes much to our understanding about the clinical effect of MET use in type 2 DM-TB co-infection.

An observational clinical study was done in type 2 DM newly TB co-infection outpatients at Surabaya Paru Hospital. Patients were divided into two groups. First group was MET group, whom was given MET accompanying insulin and TB treatment regimens, the golden standard therapy of DM-TB co-infection. MET therapy was given for at least 2 months. Second group was non MET group, were given insulin and TB treatment regimens. The lactate levels in both group were measured after 2 months.

From 42 participants, there was no case of lactic acidosis during this study period. Data was normal distribution, thus we continued analysis the difference using paired t-test with 95% confidence. There was no difference in lactate levels (p=0.396) after MET therapy compared to non MET group.

In this study, there is no evidence that MET therapy is induced lactic acidosis event nor increased of lactate blood level. Thus we concluded that MET use in type 2 DM-TB co-infection not induced lactic acidosis.

Keywords: Type 2 diabetes mellitus-tuberculosis co-infection; Metformin; Lactic acidosis

Introduction

Tuberculosis (TB) remains a major source of morbidity and mortality throughout the world; one-third of the world’s population is estimated to be infected with Mycobacterium tuberculosis where by approximately nine million people develop the disease each year, and almost two million die annually as a result [1]. DM-TB (Type 2 diabetes mellitus-tuberculosis) co-infection is associated with poor glycemic control in DM patients, thus elevated pro-inflammatory state [2-4]. People with DM had approximately three times the risk of developing TB disease as people without [2,5-10].

Metformin hydrochloride (MET), biguanide, use in type 2 diabetes mellitus for more than 60 years. MET works by inhibiting the production of hepatic glucose, reducing intestinal glucose absorption, and improving glucose uptake and utilization [11-14]. Recently, by a comprehensive in silico study, MET known has possibilities of utilizing as a combination drug with existing antibiotics for TB therapy [15] and by an extensive in vitro study. MET was reported controlling the growth of drug-resistant M. tuberculosis strains via production of mitochondrial reactive oxygen species and facilitates phagosome-lysosome fusion [16,17].

MET is not metabolised by P450 enzymes [12,13,18], thus it has no interaction with Rifampicin that could decrease the therapy efficacy. However, interaction MET and Rifampicin increases the expression of organic cation transporter (OCT1) and hepatic uptake of metformin, leading to an enhanced glucose-lowering [19,20].

In our previous study, MET were given to type 2 DM newly TB co-infection patients improved the superoxide dismutase (SOD)’s level (unpublished). SOD improvement after MET therapy is predicted to enhance antibacterial efficacy and considered to reduce the intracellular growth of M. tuberculosis. Collectively, these data indicate that MET is a promising candidate host-adjunctive therapy for enhancing the effective treatment of TB [15,16].

Although MET has several advantages in improving treatment of TB, MET use is still considered to be contraindication in many chronic conditions that may increase the risk of tissue anoxia and the development of MALA, an fatal metabolic condition, especially pulmonary diseases due to potential hypoxia exist [17,21,22].

Lactic acidosis is characterized by an elevated blood lactate concentration ( >45.0 mg/dL or >5.0 mmol/L), decreased blood pH

Copyright: © 2017 Novita BN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
(<7.35), and electrolyte disturbances with anion gap increased [17,22-29], and has signs and symptoms of inadequate oxygen (hypoxia) such as: shortness of breath; rapid breathing; paleness; sweating; nausea; muscle weakness; abdominal pain; coma [21,25,30].

The objective of this study is to assess the risk of lactic acidosis associated with MET use in patients with type 2 DM newly TB co-infection, combination with golden standard therapies, insulin and TB treatment regimens. Another objective is to evaluate levels of blood lactate, measured at during treatment.

Materials and Methods

Study design

The objective of this study was to identify clinical effect of MET to modulate host immune system and its ability of controlling the growth of intracellular M. tuberculosis. Thus, an observational clinical studies were done and carried out at outpatient ward of Surabaya Paru Hospital and Dr. Ramelan' Surabaya Naval Hospital. Patient criteria: 1) patient DM with new case of TB co-infection, whom were given insulin and TB treatment regimens; 2) positive M. tuberculosis in sputum smear; 3) patient's age was 25 to 60 years old; 4) has normal liver function and renal function; 5) not in hypoxia condition, saturation peripheral oxygen ≥92%.

During this clinical study, type 2 DM newly TB co-infection patients were divided into two groups. First group was MET group, whom were given MET accompanying insulin and TB treatment regimens, the golden standard therapy of DM-TB co-infection. MET therapy was given for at least 2 months. Second group, a comparison group, was non-MET group were given insulin and TB treatment regimens.

We evaluated MET combined with insulin and TB treatment regimens. MET therapy was given for at least 2 months. During MET therapy, as a follow up program, patients were weekly physical examination checked, thus signs and symptoms lactic acidosis were monitored. Lactate level was measured as after 2-month MET therapy, for MET group. For comparison, non MET group, whom was given insulin and TB treatment regimens, was also weekly physical examination checked and lactate level was measured after 2-month insulin and anti-TB therapy.

Diagnosis and management therapy

The diagnosis of TB was established by 1) clinical symptoms and signs of TB, such: chronic productive cough, unintentional weight loss; 2) positive sputum smear of acid-fast by microscopic Zielh-Neelsen-stained sputum slides; and 3) chest radiographs with suggestive features of TB. Diagnosis of DM was established by fasting and 2 hours after meal blood glucose. HbA1c was measured after 2 months MET therapy, as evaluation.

Patients diagnosed with TB were registered and treated with TB treatment regimens for a period of 6 months in accordance to WHO guidelines [31-33]. Management therapy for achieving good glycaemic control was insulin therapy.

This following drugs were used: MET (Metformin[34]), insulin (Humulin[35]), rifampicin (RIF), isoniazid (INH), pyrazinamide (PYR), ethambutol (ETH). MET were given 1000-1500 mg in divided daily dose for at least 2 months or during intensive phase of TB treatment, accompanying insulin therapy and TB treatment regimens.

Lactate blood measurement

After at least 2 months therapy whole blood samples, both groups, were measured by using Biosen C-line glucose and lactate analyzer[36] to test lactate blood levels [25].

Results

Characteristic of patients

During this study period, there were 476 cases of new TB infection and 156 cases (~30%) of that were type 2 DM newly TB co-infection. 42 patients, both equally male and female, were eligible participated in this observational studies (Table 1). The condition in both groups were homogenous (p>0.17; p>0.05) using Saphiro Wilk test. The youngest of patient's age was 26 years old.

Distribution of patient's eligible criteria such HbA1c, oxygen saturation, renal function (BUN, creatinine serum) and liver function (SGOT, SGPT) show in Table 2. All data were normal distributed using Saphiro Wilk test, thus, we continued analysis the data for the difference using paired t-test statistics with 95% of confidence.

Blood glucose condition for both group were similar (p=0.26), thus we dismissed the influence of hyperglycemia condition to lactate blood level [25,34].

Lactate blood level

After observation of MET therapy, on divided daily dose of 1000-1500 mg for at least 2 months accompanying insulin therapy and TB treatment regimens. Lactate blood levels were measured after 2 months MET therapy.

There was no incidence of lactic acidosis event during this period. Additionally, other side effect of MET therapy such gastrointestinal intolerance were also reported. Only two cases of mild gastrointestinal disturbance, such mild frequent diarrhea and nausea/vomiting, were reported.

Lactate blood level in both groups were normal distribution, using Saphiro Wilk test (p=0.24; p>0.05), then analyzed the difference between both group using paired t-test (Table 3; Figure 1).

Comparing MET group with non-MET group, we concluded there were no statistical significant different of lactate blood level after at least 2 months MET therapy (p>0.05). The level of lactate blood was in normal range (less than 2.50 mmol/L) both in MET group and also non MET group.

Table 1: Characteristic of Patients’ Sex and Ages.

<table>
<thead>
<tr>
<th>Sex</th>
<th>MET group</th>
<th>Non MET group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Age (x ± SD)</td>
</tr>
<tr>
<td>Male</td>
<td>11</td>
<td>44.29 ± 9.76</td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>43.45 ± 9.10</td>
</tr>
<tr>
<td>Total</td>
<td>22</td>
<td>43.78 ± 9.08</td>
</tr>
</tbody>
</table>

Table 2: Distribution of patient’s eligible criteria.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>MET group</th>
<th>Non MET group</th>
<th>p (difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (g/dL)</td>
<td>8.82 ± 1.91</td>
<td>9.52 ± 2.02</td>
<td>0.379</td>
</tr>
<tr>
<td>Oxygen saturation (SpO2) (%)</td>
<td>98.06 ± 0.73</td>
<td>97.47 ± 0.83</td>
<td>0.398</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>0.95 ± 0.16</td>
<td>0.93 ± 0.13</td>
<td>0.980</td>
</tr>
<tr>
<td>Creatinine serum (U/L)</td>
<td>23.92 ± 11.92</td>
<td>27.3 ± 12.01</td>
<td>0.103</td>
</tr>
<tr>
<td>SGOT (U/L)</td>
<td>17.63 ± 6.16</td>
<td>14.44 ± 6.48</td>
<td>0.354</td>
</tr>
<tr>
<td>SGPT (U/L)</td>
<td>19.22 ± 8.73</td>
<td>16.09 ± 7.56</td>
<td>0.509</td>
</tr>
</tbody>
</table>

Table 3: Lactate blood level.
Lacto-acidosis is also influenced by high glycemic index. To minimize the bias due to hyperglycemia, HbA1c measurement was done 2 months after the MET therapy accompanying insulin and TB treatment regimens for MET group. HbA1c, for non MET group, was also performed after 2 months of insulin and OAT therapy, or after intensive TB therapy phase was done (Table 2).

There were no MALA cases during this 2-month study, both for MET and non MET groups. It was even proved that blood lactate level was in normal range (<2.50 mmol/L). The blend of MET, insulin and TB treatment was relatively safe for DM-TB patients if some condition was controlled (Table 3).

In this study, we also found that the participants (<5%) in MET group experienced mild gastrointestinal intolerance (nausea and vomit). This can be related to high concentrated MET or glucose metabolism change causing local irritation, fluid retention, and salt mal-absorption, leading to loose stools and diarrhoea [17].

In this study, we were not yet involved TB patients non Type 2 DM, even in our knowledges MET, which has low hypoglycemic effect, could be beneficial in TB patients non DM due to anti-inflammatory effect and increasing efficacy of TB treatment [16,40]. In future, after establishing MET clinical effect in type 2 DM-TB co-infection, we may combine MET therapy with anti TB for TB patients non Type 2 DM in order to evaluate the efficacy of MET therapy in immune modulation.

Conclusions

Lactic acidosis in MET therapy is rare but important adverse event and clearly we need to prevent it. In this case risk study, there is no evidence of MALA. The elevation levels of lactate, compared with placebo were also not occured. Thus we concluded that MET use in type 2 DM-TB co-infection not induced lactic acidosis. Furthermore, this result, due to our limitation in number of participants that involved in the study, need to be confirmed in a cohort study.

Acknowledgements

We thank Sri Hastuti and team (Clinical Pathology, Diagnostic Center Dr. Soetomo Hospital, Surabaya, Indonesia) for her technical assistance. We thank Prof. Dr. Yusak, dr., M.S., Sp.PK (K) for the discussion. This study was supported in part by grant – aid for Ph.D research from Lembaga Pengelola Dana Pendidikan (LPDP), the Ministry of Economic and the Ministry Education, Research and Technology of Republic of Indonesia.

References


